US FDA issues warning letter to Aurobindo Pharma subsidiary Eugia Pharma

Pharmaceuticals

14 August 2026 at 1:38 pm

US FDA issues warning letter to Aurobindo Pharma subsidiary Eugia Pharma

HyperFast News

Summary

The U.S. FDA has issued a warning letter to Eugia Pharma, a subsidiary of Aurobindo Pharma, following earlier observations and an Official Action Indicated (OAI) status at its Hyderabad manufacturing unit.

Select what you want to create

Turn this story into an image post, carousel, video, audio reel, blog, and more — all from HyperFast News.

FAQ

Newsroom FAQs

About the public HyperFast News news feed powered by NewsEngine.